Exhaled Breath Condensate Biomarkers in CARAS
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: questionnaire survey.
- Who it may be relevant to
- Registry conditions: Combined Allergic Rhinitis and Asthma Syndrome. Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Preliminary Application and Evaluation of Exhaled Breath Condensate Biomarkers in Combined Allergic Rhinitis and Asthma Syndrome (CARAS)
Overview
To explore the differences in the expression of biomarkers in different sample types between the healthy population and different subgroups of the disease, and to screen for potential biomarkers in a more simple, direct and objective way. To screen the biomarkers that can be identified by CARAS Chinese medicine symptoms and different stages, and to provide a reference basis for individualised diagnosis and treatment of the disease.
Interventions
- Other questionnaire survey
subjects fill out questionnaires
Primary outcome measures
- Interleukin-2、4、5、13 (IL-2、4、5、13) [Time frame: Basline]
- Interferon-γ (IFN-γ) [Time frame: Basline]
- Tumor necrosis factor-β (TNF-β) [Time frame: Basline]
- Eosinophil cationic proteins (ECP) [Time frame: Basline]
- Immunoglobulin E (IgE) [Time frame: Basline]
Secondary outcome measures (5)
- Fractional exhaled nitric oxide (FeNO) [Time frame: Basline]
- Forced expiratory volume in one second (FEV1) [Time frame: Basline]
- Forced vital capacity (FVC) [Time frame: Basline]
- FVC as the percentage of the predicted value (FVC%) [Time frame: Basline]
- Forced expiratory volume in one second / forced vital capacity (FEV1/FVC) [Time frame: Basline]
Eligibility criteria
Inclusion criteria
- Patients with AR, BA and CARAS who meet the Western medical diagnostic criteria;
- Chinese medical evidence consistent with lung qi deficiency evidence, phlegm-heat congestion of the lung evidence, or wind-heat offending the lung evidence;
- Age 18 to 80 years;
- Voluntarily accepted the study and signed an informed consent form;
- Not participated in other clinical studies within 1 month before enrollment.
Exclusion criteria
- Patients with combined vasomotor rhinitis and eosinophilic non-allergic rhinitis, other non-allergic rhinitis diseases that can cause symptoms such as nasal congestion and runny nose;
- Patients who are participating in other drug trials;
- Patients with a combination of other serious systemic diseases;
- Pregnant or lactating women;
- Patients with confusion, disorders of consciousness, dementia, and various psychiatric disorders.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Other
Study locations
China · 1 center
- The First Affiliated Hospital of Henan University of Chinese Medicine — Henan
Identifiers
NCT: NCT06573450 · EBC biomarkers in CARAS